No abstract available
Keywords:
amiodarone; dry powder inhaler; electro-spraying; nanocrystal; nasal formulations; pulmonary delivery.
PubMed Disclaimer
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Advances in orally inhaled and nasal drug products (OINDPs)
References
-
-
Dalvi A., Ravi P. R., Uppuluri C. T. (2022). Design and evaluation of rufinamide nanocrystals loaded thermoresponsive nasal in situ gelling system for improved drug distribution to brain. Front. Pharmacol. 13, 943772. 10.3389/fphar.2022.943772
-
DOI
-
PMC
-
PubMed
-
-
Pires P. C., Rodrigues M., Alves G., Santos A. O. (2022). Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs. Pharmaceutics 14 (3), 588. 10.3390/pharmaceutics14030588
-
DOI
-
PMC
-
PubMed
-
-
Rajput A., Pingale P., Dhapte-Pawar V. (2022). Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects. Front. Pharmacol. 13, 979682. 10.3389/fphar.2022.979682
-
DOI
-
PMC
-
PubMed
-
-
Ruzgys P., Böhringer S., Dokumaci A. S., Hari Y., Schürch C. M., Brühl F., et al. (2021). Electrospray mediated localized and targeted chemotherapy in a mouse model of lung cancer. Front. Pharmacol. 12, 643492. 10.3389/fphar.2021.643492
-
DOI
-
PMC
-
PubMed
-
-
Siswanto S., Yamamoto H., Furuta H., Kobayashi M., Nagashima T., Kayanuma G., et al. (2021). Drug repurposing prediction and validation from clinical big data for the effective treatment of interstitial lung disease. Front. Pharmacol. 12, 635293. 10.3389/fphar.2021.635293
-
DOI
-
PMC
-
PubMed